Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 203-470-7 | CAS number: 107-18-6
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Basic toxicokinetics
Administrative data
- Endpoint:
- basic toxicokinetics in vitro / ex vivo
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Data taken from a peer reviewed publication
Data source
Reference
- Reference Type:
- publication
- Title:
- The biotransformation of allyl alcohol and acrolein in rat liver and lung preparations.
- Author:
- Patel, J.M., Wood., J.C., Leibman, K.C.
- Year:
- 1 980
- Bibliographic source:
- Drug metabolism and disposition 8: 305-308
Materials and methods
- Objective of study:
- metabolism
Test guideline
- Qualifier:
- no guideline followed
- Principles of method if other than guideline:
- This study identifies and characterises the pathways of biotransformation of allyl alcohol by rat liver and lung preparations.
- GLP compliance:
- not specified
Test material
- Reference substance name:
- Allyl alcohol
- EC Number:
- 203-470-7
- EC Name:
- Allyl alcohol
- Cas Number:
- 107-18-6
- Molecular formula:
- C3H6O
- IUPAC Name:
- prop-2-en-1-ol
- Details on test material:
- Allyl alcohol was obtained from Eastman Kodak Corp. (Rochester, N.Y.). The purity of allyl alcohol used is not known.
Constituent 1
- Radiolabelling:
- no
Test animals
- Species:
- rat
- Strain:
- other: Holtzman
- Sex:
- male
- Details on test animals or test system and environmental conditions:
- Male Holtzman rats (approximately 120-130 g body weight) were pretreated with 75/mg/kg sodium phenobarbital for 3 days. From these rats, liver cytosol and microsomes were isolated. In addition lung cytosol and microsomes were also isolated.
Administration / exposure
- Route of administration:
- other: in vitro test
- Vehicle:
- not specified
- Details on exposure:
- Experiments carried out in vitro using reconstituted lyophilised liver or lung 9000g supernatant fractions.
- Duration and frequency of treatment / exposure:
- See 'Details on study design' field.
Doses / concentrations
- Remarks:
- Doses / Concentrations:
See 'Details on study design' field.
- Control animals:
- other: in vitro control used
- Details on study design:
- Metabolism of allyl alcohol to acrolein: studied using a reaction mixture containing 1.0 mM NAD+, 5.0 mM MgSO4, 5.0 mM allyl alcohol and reconstituted lyophilised liver or lung 9000g supernatant fraction (equivalent to 45mg of protein or 15 or 25 mg of microsomal or cytosolic protein respectively) in 3.0 ml of 0.1M Tris-HCl buffer (pH 7.5). 0.5 mM pyrazole was used to inhibit alcohol dehydrogenase. Each reaction flask was incubated at 37°C for 45 minutes. After incubation each reaction flask was placed into an icebath and 1.0 ml of 70% HClO4 added. This mixture was then centrifuged (1400 rpm for 10 minutes) and the supernatant was mixed with 5.0ml of solution containing 0.1% 2,4-dinitrophenylhydrazine (DNPH) in 0.2 N HCl and kept overnight. The acrolein-DNPH derivative formed was extracted in 10.0 ml of HPLC-grade chloroform. The extract was washed with 2 N HCl and distilled water to remove excess DNPH. The acrolein was concentrated to dryness using nitrogen. Dried samples were dissolved in methylene chloride to be analysed by HPLC.
Metabolism of allyl alcohol to acrylic acid: Studied using a reaction mixture consisting of 1.0 mM NAD+, 5.0 mM MgSO4, 5.0 mM allyl alcohol and reconstituted lyophilised liver or lung 9000g supernatant fraction (equivalent to 45mg of protein or 15 or 25mg of cytosolic or microsomal protein respectively in 3.0ml of 0.1M Tris-HCl buffer (pH 7.5). 0.5 mM disulfram was used for aldehyde hydrogenase inhibition. Each reaction flask was incubated at 37°C for 45 minutes and then terminated by the addition of 1.5ml of 6N HCL.
Metabolism of acrolein to acrylic acid: Studied using a reaction mixture consisting of 1.0 mM NAD+ or NADP+, 5.0 mM MgSO4, 5.0 mM acrolein and reconstituted lyophilised liver or lung 9000g supernatant fraction (equivalent to 45mg of protein or 15 or 25mg of cytosolic or microsomal protein respectively in 3.0ml of 0.1M Tris-HCl buffer (pH 7.5). 0.5 mM disulfram was used for aldehyde hydrogenase inhibition. Each reaction flask was incubated at 37°C for 45 minutes and then terminated by the addition of 1.5ml of 6N HCL. Each reaction flask was centrifuged (1400 rpm for 10 minutes) and the acrylic acid extracted from the supernatant using 10ml ether. The ether layer was concentrated to 10-15 ul using nitrogen and subsequently added to 0.8ml of HPLC grade methylene chloride. 200 ul of a 1.0 mM solution of PNBDI in methylene chloride and heated at 80°C for 2 hours. This was then analysed by HPLC.
Formation of glycidol and glycidaldehyde (microsomal oxidation products of allyl alcohol and acrolein respectively): 3.0 mM of allyl alcohol or acrolein were incubated with 10 or 15mg of liver or lung microsomal protein in a 3.0ml incubation mixture. After incubation for 5 minutes at 37°C, the reaction flasks were placed into an icebath for 18 minutes after the addition of the substrate. Methanol was added to each reaction flask for deproteinisation and centrifuged (at 1400 rpm for 10 minutes). The supernatant was filtered through a 0.45u Millipore filter and the filtrate dried under an airstream. The residue was extracted using ethyl acetate and after centrifugation the ethyl acetate layer was concentration under nitrogen and analysed using gas and thin-layer chromatography.
Hydration of glycidol and glycialdehyde by liver microsomal epoxide hydrase: acrolein was incubated with liver and lung microsomes at 37°C for 60 minutes. Additionally 0.1 mM glycialdehyde was incubated with 10 or 15 mg of liver or lung microsomal protein respectively in 3.0 ml volumes (also containing 0.1 M Tris-HCl buffer) at 37°C for 60 minutes. Each reaction was terminated by the addition of methanol. Each reaction flask was centrifuged (1400 rpm for 10 minutes) and the supernatant evaporated under an airstream. 1.0 ml of distilled was added to the residue and once again centrifuged. The supernatant from this was used in the determination of glyceraldehydes content by a spectrophotometric method.
Formation of glycerol or glycidol by liver microsomes with allyl alcohol: Two incubation mixtures were used. Incubation mixture A contained: 0.75 mM nicotinamide, 0.5 mM MgSO4, 60 uM EDTA, 30 uM ATP, 0.25 mM glucose 6-phosphate, 0.1 mM NADP+, 10 units of glucose 6-phosphate dehydrogenase, 100 mg of liver microsomal proteins and 5.0 mM allyl alcohol. Incubation mixture B contained: 1.0 mM glycidol and 15 mg of liver or lung microsomal protein in a volume of 5.0 ml (containing 0.1 M Tris-HCl buffer). Both incubation mixed were incubated along with a control (containing no substrates) at 37C for 60 minutes. 200 g of NaCl was added to mixture A and 15 g to mixture B to terminate the reactions. The contents of mixtures A and B were extracted using 150 ml and 10 ml isopropyl alcohol respectively. Mixtures were centrifuged (200- rpm for 15 minutes) and the isopropyl alcohol layer was removed and evaporated to dryness under an airstream. 20 ml and 2 ml of isopropyl alcohol were added to residues A and B and once again centrifuged. The isopropyl layer was removed and evaporated to dryness. The residues were dissolved into 0.2 ml of pyridine and analysed by modified HPLC and mass spectrometry.
Results and discussion
Metabolite characterisation studies
- Metabolites identified:
- yes
- Details on metabolites:
- Acrolein, acrylic acid, glycidol, glycidaldehyde and glyceraldehyde.
Any other information on results incl. tables
The metabolic conversion of allyl alcohol to acrolein (table 1) and further metabolism to acrylic acid has been confirmed in liver 9000g supernatant fractions and cytosol in the presence of NAD+. Allyl alcohol metabolism to acrolein was not seen when NAD+ was replaced with NADP+ or NADPH or in liver microsomes with NAD+. 80% of allyl alcohol was metabolised to acrolein when liver 9000g supernatant and cytosol fractions were used. In addition, when lung fractions are used, allyl alcohol does not appear to be metabolised to acrolein.The presence of pyrazole appeared to inhibit the metabolism of allyl alcohol to acrolein in both 9000g and cytosol fractions.
Acrolein which was formed in allyl alcohol metabolism was further metabolised to acrylic acid (however, only 15% of the acrolein was metabolised to acrylic acid). The presence of pyrazole seemed to affect the formation of acrylic acid.
Metabolism of acrolein to acrylic acid (see table 2) was seen in liver 9000g supernatant, cytosolic and microsomal preparations (in presence of NAD+ or NADP+). Acrylic acid was not present when NADPH was used in the liver incubation mixture or if lung preparations were used.
Incubation of allyl alcohol and acrolein with liver and lung microsomes (with NADPH), revealed that glycidol and glycidaldehyde were formed.
Hydration of these epoxides glycidol and glycidalehyde to glycerol and glyceraldehyde respectively were seen when incubated with liver or lung microsomal preparations. (see table 3). When boiled microsomes were used, neither glycerol or glyceraldehyde were formed.
Table 1. Metabolism of allyl alcohol to acrolein and acrylic acid by rat liver fractions.
Metabolite production (nmol/min/mg protein) | Acrolein | Acrylic acid | ||
9000g | Cytosol | 9000g | Cytosol | |
No additions | 0.0 +/- 0.0 | 0.0 +/- 0.0 | 0.0 +/- 0.0 | 0.0 +/- 0.0 |
NAD+ added | 45.4 +/- 4.8 | 36.2 +/- 3.9 | 4.3 +/- 0.5 | 3.1 +/- 0.2 |
NAD+ & pyrazole (0.5 mM) | 13.7 +/- 1.2* | 11.0 +/- 1.2 * | 0.0 +/- 0.0 | 0.0 +/- 0.0 |
NAD+ & disulfiram (0.5 mM) added | 40.8 +/- 3.0 | 31.2 +/- 3.6 | 1.2 +/- 0.3 * | 0.9 +/- 0.1* |
* Significantly different from uninhibited reactions (p < 0.01)
Table 2. Metabolism of acrolein to acrylic acid by rat liver fractions
Acrylic acid (nmol/min/mg protein) | |||
9000g | Cytosol | Microsomes | |
No additions | 0.0 | 0.0 | 0.0 |
NAD+ added | 15.6 +/- 1.3 | 11.1 +/- 0.8 | 4.0 +/- 0.2 |
NAD+ + disulfram (0.5mM) added | 6.2 +/- 0.8* | 3.2 +/- 0.2* | 0.0 +/- 0.0* |
NADP+ added | 4.8 +/- 0.3 | 3.2 +/- 0.4 | 1.5 +/- 0.1 |
NADP+ + disulfram (0.5mM) added | 0.9 +/- 0.1* | 0.0 +/- 0.0* | 0.0 +/- 0.0* |
* Significantly different from uninhibited reactions (p < 0.01)
Table 3. Liver and lung microsomal hydration of glycidol and glycidaldehyde
Liver | Lung | |||
Glycerol | Glyceraldehyde | Glycerol | Glyceraldehyde | |
umol/mg protein | ||||
No additions | 0.0 | 0.0 | 0.0 | 0.0 |
NADPH added | 0.0 | 0.0 | 0.0 | 0.0 |
Allyl alcohol added | 0.0 | - | 0.0 | - |
Acrolein added | - | 0.0 | - | 0.0 |
Allyl alcohol + NADPH added | 0.32 | - | - | - |
Acrolein + NADPH added | - | 1.33 | - | 1.02 |
Glycidol added | 0.44 | - | 0.15 | - |
Glycidaldehyde added | - | 1.55 | - | 1.2 |
Glycidol added# | 0.0 | - | 0.0 | - |
Glycidaldehyde added# | - | 0.0 | - | 0.0 |
# Boiled microsomes were used
Applicant's summary and conclusion
- Conclusions:
- Interpretation of results (migrated information): other: Biotransformation pathways determined
This study demonstrated metabolic conversion of allyl alcohol to acrolein in liver fractions (cytosol, 9000g supernatant) but not liver microsomes. In liver and lung microsomes, allyl alcohol is converted to glycidol; further metabolism of acrolein to glyceraldehyde or acrylic acid, glycidol to glycerol is microsome-mediated.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
